CD52 and graft versus host disease: To mitigate the risk of graft-versus-host disease (GVHD) associated with ALLO-316, modifications were made, including the disruption of the TCR alpha and a CD52 knockout, which allowed for ALLO-647 (anti-CD52 antibody) to deplete host T-cells and promote the persistence of allogeneic CAR T-cells [93].